Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03887650 · ClinicalTrials.gov registry record · Phase 4
LIBERATE - LIposomal Bupivacaine vERsus Adjuncts in Total shouldErs
A Phase 4 study, sponsored by Hartford Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
NCT03887650 is a Phase 4 study that has completed, run by Hartford Hospital. The registered enrollment target is 90 participants.
The verdict
NCT03887650, a Phase 4 study, has completed, sponsored by Hartford Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
Study Summary
This will be a single-center, prospective, randomized controlled cross-sectional study comparing interscalene brachial plexus block with liposomal bupivacaine versus bupivacaine with epinephrine and PF dexamethasone in patients undergoing primary shoulder arthroplasty. Primary endpoint will be total opioid consumption in the first three post-operative days.
Interventions
- DRUG Bupivacaine 0.5%
- DRUG Liposomal Bupivicaine 1.3%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2019-03-11 |
| Est. Completion | 2022-03-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03887650
The ClinicalTrials.gov registry entry for NCT03887650 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hartford Hospital, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bupivacaine 0.5% is the first listed.
NCT03887650 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03887650 about?
NCT03887650 is a clinical study titled "LIBERATE - LIposomal Bupivacaine vERsus Adjuncts in Total shouldErs". This will be a single-center, prospective, randomized controlled cross-sectional study comparing interscalene brachial plexus block with liposomal bupivacaine versus bupivacaine with epinephrine and PF dexamethasone in patients undergoing primary shoulder arthroplasty. Primary endpoint will be total...
What is the current status of trial NCT03887650?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2019-03-11. Estimated completion is 2022-03-08.
What interventions are being tested in trial NCT03887650?
The interventions under investigation include: Bupivacaine 0.5% (DRUG), Liposomal Bupivicaine 1.3% (DRUG).
Who is sponsoring clinical trial NCT03887650?
This trial is sponsored by Hartford Hospital, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.